4D Advisors LLC Invests $1.89 Million in RxSight, Inc. (NASDAQ:RXST)

4D Advisors LLC acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 55,000 shares of the company's stock, valued at approximately $1,891,000. 4D Advisors LLC owned approximately 0.14% of RxSight at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of RXST. Vanguard Group Inc. grew its position in shares of RxSight by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after purchasing an additional 96,464 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in RxSight by 32.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock valued at $53,345,000 after buying an additional 381,389 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of RxSight by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 830,758 shares of the company's stock worth $28,568,000 after acquiring an additional 13,641 shares during the last quarter. DF Dent & Co. Inc. purchased a new position in shares of RxSight during the 4th quarter worth $14,524,000. Finally, Northern Trust Corp boosted its position in shares of RxSight by 6.9% during the 4th quarter. Northern Trust Corp now owns 403,404 shares of the company's stock valued at $13,869,000 after acquiring an additional 26,106 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RXST shares. Piper Sandler started coverage on shares of RxSight in a research note on Tuesday, April 15th. They set a "neutral" rating and a $18.00 target price on the stock. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 price objective (down from $40.00) on shares of RxSight in a report on Friday, April 4th. Needham & Company LLC reissued a "buy" rating and set a $43.00 target price on shares of RxSight in a research note on Thursday, April 3rd. UBS Group lowered RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the company from $45.00 to $16.00 in a research note on Wednesday, April 9th. Finally, Wells Fargo & Company cut their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating for the company in a research report on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $37.60.

Insider Buying and Selling

In other news, Director Tamara Fountain sold 7,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares of the company's stock, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 9.36% of the company's stock.

RxSight Trading Up 5.8 %

NASDAQ:RXST traded up $0.87 during midday trading on Friday, reaching $15.85. The company had a trading volume of 1,534,001 shares, compared to its average volume of 648,273. RxSight, Inc. has a 12-month low of $13.50 and a 12-month high of $66.54. The firm has a market capitalization of $643.83 million, a price-to-earnings ratio of -19.10 and a beta of 1.26. The stock's fifty day simple moving average is $20.67 and its 200-day simple moving average is $32.52.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to analysts' expectations of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. As a group, sell-side analysts expect that RxSight, Inc. will post -0.7 EPS for the current year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.